Inhibikase Therapeutics clinical trials we track

Check company identity source

Phase 3 2 trials

TrialDrugs studiedStatusPrimary completion
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)NCT07365332IKT-001Recruiting2029-06Estimated
Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)NCT07632898IKT-001Not yet recruiting2030-06-30Estimated

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: [Part A] To evaluate the effect on PVR in participants with WHO Group 1 PAH treated with IKT-001 compared to placebo Measure: [Part B] To characterize the effects of IKT-001 on symptoms and characteristics of Pulmonary Arterial Hypertension compared to placebo. After: Measure: [Part A] To evaluate the effect on Pulmonary Vascular Resistance (PVR) in participants with WHO Group 1 PAH treated with IKT-001 compared to placebo Measure: [Part B] To characterize the effects of IKT-001 on symptoms and characteristics of Pulmonary Arterial Hypertension compared to placebo.

Check registry source